Research suggests the common table mushroom has anti- aromatase  properties and therefore possible anti-estrogen activity. In 2009, a case-control study of the eating habits of 2,018 women in southeast China revealed that women who consumed greater than 10 grams of fresh mushrooms or greater than 4 grams of dried mushrooms per day had an approximately 50% lower incidence of breast cancer. Chinese women who consumed mushrooms and green tea had a 90% lower incidence of breast cancer.  However the study was relatively small (2,018 patients participating) and limited to Chinese women of southeast China.
The VIGOR (Vioxx Gastrointestinal Outcomes Research) trial, "which was the making of Merck's drug rofecoxib (Vioxx),"  was at the center of a dispute about the ethics of medical journals. VIGOR trial,1 was a trial in which over 8000 patients were randomized to receive either naproxen or rofecoxib (Vioxx), a Cox-2 inhibitor that Merck hoped would have fewer gastrointestinal side effects."  Both publications concluded that COX-2 specific NSAIDs were associated with significantly fewer adverse gastrointestinal effects. In the CLASS trial comparing Celebrex 800 mg/day to ibuprofen 2400 mg/day and diclofenac 150 mg/day for osteoarthritis or rheumatoid arthritis for six months, Celebrex was associated with significantly fewer upper gastrointestinal complications (% vs. %, P=), with no significant difference in incidence of cardiovascular events in patients not taking aspirin for cardiovascular prophylaxis .